Physician profile
Sunita Kumar
NPI 1962642801
$719.52
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $63.00 · 2022: $13.68.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $276.77 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.96 | 2019-2020 | |
| Lundbeck LLC | $56.98 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $51.42 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $49.78 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.42 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $42.27 | 2019 | |
| Shire North American Group INC | $32.89 | 2019 | |
| Allergan, INC. | $32.79 | 2019-2020 | |
| Neuronetics, INC. | $28.96 | 2019 | |
| Neos Therapeutics, LP | $16.53 | 2019 | |
| Abbvie INC. | $13.68 | 2022 | |
| Adlon Therapeutics L.P. | $11.07 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunita Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.